In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apyx Medical Corporation

https://apyxmedical.com/

Latest From Apyx Medical Corporation

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Inflammation ImmunoOncology

Mustang Bio Enters Race For CAR-T In Autoimmune Disease

The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.

ImmunoOncology Business Strategies

Mustang Bio’s MB-101 Gallops To Win In Glioblastoma

The lead author on the Phase I study told Scrip that in addition to targeting a widely expressed antigen on GBM tumors, the CAR-T also stimulates the body’s immune system.

ImmunoOncology Clinical Trials

Janssen Gives Next-Gen CAR-Ts Another Shot After Fate Deal’s Collapse

A new collaboration with Cellular Biomedicine includes a CD19/CD20-directed bispecific CAR-T in Phase I development for B-cell non-Hodgkin lymphomas.

Deals ImmunoOncology
See All

Company Information

  • Industry
  • Medical Devices
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Other Names / Subsidiaries
    • Bovie Bulgaria
    • Bovie Medical Corporation
UsernamePublicRestriction

Register